GLP1R and type 2 diabetes mellitus: However, further research is required to establish how to use these drugs to produce optimal outcomes for kidney pathology.263 The outcomes of the currently ongoing FLOW study will further inform the therapeutic potential of GLP-1R analogues to improve renal and cardiovascular prognosis in patients with renal impairment and T2D.265,266